Evaxion Announces Business Update and Second Quarter 2023 Financial Results

Promising clinical data from Phase 1 and 2a studies with EVX-01 and EVX-02 were presented at AACR and ASCO in Q2 2023A novel proprietary genetic vaccine adjuvant was presented at Evaxion’s R&D Day...

Related Keywords

Denmark ,Russia ,Copenhagen ,Køavn ,New Hampshire ,United States ,New York ,Ukraine ,American , ,Global Growth Holding Limited ,Exchange Commission ,Staphylococcal Diseases Gordon Research Conference ,Securities Exchange ,Global Growth Holding ,Per Norl ,Chief Executive Officer ,Gordon Conference ,American Society ,Clinical Oncology ,American Association ,Cancer Research ,Nasdaq New York ,Securities Act ,Securities Exchange Act ,Annual Report ,Financial Position Data ,Comprehensive Loss Data ,Evaxion Biotech ,Markets ,